Literature DB >> 28150214

Exploiting Uptake of Nanoparticles by Phagocytes for Cancer Treatment.

Mee Rie Sheen1, Steven Fiering2,3,4.   

Abstract

Many cancers including ovarian, pancreatic, colon, liver, and stomach cancers are largely confined to the peritoneal cavity. Peritoneal tumors are directly accessible by intraperitoneal injections. Previously we demonstrated that intraperitoneal injection of nanoparticles and subsequent ingestion by tumor-associated phagocytes can be used to either directly impact tumors or stimulate antitumor immune responses. Here we outline methods to specifically utilize iron oxide nanoparticles with the ID8-Defb29/Vegf-A murine ovarian cancer model and discuss the tendency of phagocytes to ingest nanoparticles and the potential of phagocytes to carry nanoparticles to tumors resulting in direct killing of tumor cells or stimulate antitumor immune responses in peritoneal cancers. This basic approach can be modified as needed for different types of tumors and nanoparticles.

Entities:  

Keywords:  Antitumor immune responses; ID8-Defb29/Vegf-A; Intraperitoneal injection; Iron oxide nanoparticles; Nanoparticles; Ovarian cancer; Peritoneal cavity; Peritoneal tumor; Tumor-associated phagocytes

Mesh:

Substances:

Year:  2017        PMID: 28150214     DOI: 10.1007/978-1-4939-6646-2_22

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.

Authors:  Toni K Choueiri; Michael B Atkins; Ziad Bakouny; Maria I Carlo; Charles G Drake; Eric Jonasch; Payal Kapur; Bryan Lewis; W Marston Linehan; Michael J Mitchell; Sumanta K Pal; Kevin Pels; Susan Poteat; W Kimryn Rathmell; Brian I Rini; Sabina Signoretti; Nizar Tannir; Robert Uzzo; Christopher G Wood; Hans J Hammers
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

Review 2.  Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.

Authors:  Giovanni Di Lorenzo; Giuseppe Ricci; Giovanni Maria Severini; Federico Romano; Stefania Biffi
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.